<DOC>
	<DOCNO>NCT01775592</DOCNO>
	<brief_summary>Resistance Plasmodium falciparum toward Artemisinins , important drug successful treatment malaria , confirm Cambodia . There report neighbour country delay parasite rate . The investigator therefore aim ass parasite clearance malaria patient central Vietnam treat accord national standard guideline .</brief_summary>
	<brief_title>Plasmodium Falciparum Artemisinin Resistance Vietnam</brief_title>
	<detailed_description>General objective To evaluate efficacy DHA-PPQ patient uncomplicated falciparum malaria rural area Central Vietnam , assess vitro susceptibility P.falciparum isolate DHA PPQ . Specific objectives 1 . To measure parasite clearance time falciparum malaria patient treat DHA-PPQ . 2 . To determine efficacy DHA-PPQ day 42 post-treatment . 3 . To assess vitro susceptibility P.falciparum isolate towards DHA PPQ Quang Nam Province . 4 . To compare genetic profile P.falciparum isolate delay normal clearance time order identify potential marker resistance ;</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<criteria>Age : 6 month age ; Fever ( body temperature 37.5C ) history fever previous 24 hour ; Monoinfection P.falciparum parasite density 500100,000/µl Written inform consent participate trial . For patient age less 18 year , inform consent obtain parent guardian . Mixed malaria infection ; Pregnancy lactation ( urine test β human chorionic gonadotropin perform woman child bear age unless menstruate ) ; Concomitant acute illness necessitate specific treatment ( antibiotic ) ; Underlying chronic severe illness ( e.g . cardiac , renal , hepatic disease , HIV/AIDS ) . Severe malnutrition ; Danger sign : able drink incontrollable vomit recent history convulsion ( &gt; 1 24 hour ) unconscious state ; neurological impairment unable sit stand Signs severe malaria : 1 . Cerebral malaria ( unrousable coma ) 2 . Severe anaemia ( Htc &lt; 15 % ) 3 . Renal failure ( serum creatinine &gt; 3 mg/dL ) 4 . Pulmonary oedema ; 5 . Hypoglycemia ( &lt; 40mg/dL ) 6 . Shock ( systolic BP &lt; 70 mmHg adult , 50 child ) 7 . Spontaneous bleed 8 . Repeat generalize convulsion 9 . Macroscopic haemoglobinuria 10 . Severe jaundice Persons receive quinine , artemisinin artemisinin derivative within last 7 day , 4aminoquinolines within last 14 day , pyrimethamine and/or sulfonamide within last 28 day , mefloquine within last 56 day exclude vitro testing</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>P.f resistance</keyword>
</DOC>